Table 2.
Vaccine effectiveness by dose and vaccine type in all ages and within age categories against COVID-19
|
One dose |
Two doses |
Three doses |
||||
|---|---|---|---|---|---|---|
| BNT162b2 | CoronaVac | BNT162b2 | CoronaVac | BNT162b2 | CoronaVac | |
| Mild or moderate disease | ||||||
| 20–59 years | 39·9% (24·8–52·3) | 32·7% (14·4–47·6) | 35·1% (26·6–42·5) | 25·1% (14·7–34·3) | 73·5% (66·6–79·2) | 51·0% (39·6–60·4) |
| ≥60 years | None* | None* | None* | None* | 70·2% (53·3–82·0) | 32·4% (8·3–51·0) |
| Severe or fatal disease | ||||||
| 20–59 years | 95·4% (90·7–98·1) | 74·8% (63·7–82·8) | 96·3% (94·9–97·3) | 91·7% (88·7–94·0) | 98·6% (97·5–99·3) | 98·8% (97·5–99·5) |
| 60–69 years | 70·0% (51·8–82·0) | 54·2% (36·4–67·3) | 91·1% (86·9–94·0) | 79·3% (71·8–85·0) | 98·9% (97·3–99·6) | 97·4% (95·2–98·7) |
| 70–79 years | 72·2% (56·7–82·6) | 29·2% (7·4–46·1) | 89·8% (85·1–93·1) | 74·3% (66·5–80·3) | 99·0% (97·4–99·7) | 95·4% (92·2–97·4) |
| ≥80 years | 75·0% (61·1–84·2) | 39·0% (20·9–53·0) | 86·9% (80·5–91·3) | 58·2% (45·1–68·2) | 97·1% (93·8–98·7) | 97·3% (94·9–98·7) |
| Death | ||||||
| 20–59 years | 96·7% (90·9–99·2) | 78·2% (64·9–86·9) | 96·8% (95·1–98·0) | 93·3% (89·9–95·6) | 99·2% (97·9–99·7) | 99·4% (98·1–99·9) |
| 60–69 years | 77·6% (59·9–88·4) | 65·6% (49·8–76·8) | 92·7% (88·6–95·4) | 84·3% (77·8–89·0) | 99·0% (97·2–99·8) | 99·0% (97·3–99·8) |
| 70–79 years | 80·5% (66·3–89·2) | 45·3% (25·1–60·3) | 92·3% (88·0–95·2) | 76·7% (68·5–82·8) | 99·4% (97·9–99·9) | 97·0% (94·2–98·6) |
| ≥80 years | 78·7% (65·5–87·0) | 44·8% (26·9–58·4) | 90·3% (84·9–93·9) | 63·0% (50·3–72·5) | 97·5% (94·2–99·0) | 97·9% (95·7–99·1) |
Data are effectiveness (95% CI).
*
No evidence of protection based on a negative or very small positive point estimate and wide CIs.